Our group assessed MGMT and GFAP co-expression with fluorescence IHC (Automated QUantitative Analysis—AQUA) and demonstrated that IHC may be a better prognostic test than the DNA methylation tests for patient stratification in GBM clinical trials [39]. The gene discussed is MGMT; the disease is glioblastoma.